Tag Archives: news

The Concession Stand at the Cliff’s Edge: The End of Governance

Posted on by
Reply

By Andrew Klein 

They are not building a civilization. They are running a concession stand at the edge of a cliff, arguing over the price of peanuts while the ground crumbles beneath them.

This is not a metaphor. It is the operating principle of our time.

Look around. The evidence is in the flicker of your lights and the drop of your wifi—the cascading failure of basic infrastructure, met with a theatrical shrug. It is in the quiet, accepted tragedy that people died during a telecommunications outage, their lives reduced to a temporary public relations problem.

This failure of foresight and fundamental duty is not confined to the power grid. It is the very air we breathe, the society we inhabit. Observe the pattern, right across the spectrum:

· On Climate Change: We are offered magical thinking and faith in future technology while the planet burns. The ultimate long-term threat is met with the shortest of short-term political calculations.

· On Social Fabric: We see a deliberate erosion of the safety net—housing insecurity, food insecurity, children in poverty—all while the machinery of revenue collection, fines, and punitive measures grinds on with ruthless efficiency. The state is increasingly adept at taking, and abdicating its role in providing.

· On “Security”: We embark on grandiose, multi-generational military spending programs like AUKUS, a fortress mentality projected outward, while the domestic foundations of national strength—healthy, educated, and secure citizens—are left to rot. We are building a battleship while the crew is starving.

· On Morality: We witness a genocide in Gaza and a government that, through word and deed—from allowing the export of weapons components to offering diplomatic cover—becomes complicit. The same leaders who provide photo-ops at food banks, celebrating the “kindness” of multinational corporations that profit from the very inequality that creates the need for charity, have normalized a profound moral bankruptcy.

This is the “new normal”: a world where we are expected to accept the unacceptable. Where locking up children for so-called ‘adult’ offences is just another line in a budget, while the real, adult failures of leadership go unpunished.

The system is not failing. It is functioning exactly as designed—to preserve itself and the flows of power and profit, even at the cost of its own people and its own future. The billing continues. The performances of governance continue. But the project of building a just, resilient, and moral society has been abandoned.

The most damning part is that we are no longer surprised. We have been conditioned to expect the concession stand to run out of peanuts, for the cliff to erode further, and for the bill for this monumental inaction to be paid in lives, stability, and a habitable planet.

To be unsurprised is to be complicit. It is time to be outraged again. It is time to demand more than peanuts from the edge of the abyss.

The Great Pill Heist: How Big Pharma Targets Your Health and Your Wallet

Posted on by
Reply

By Andrew Klein   18th November 2025

They are not just selling medicine. They are selling a doctrine: that your health is a product, and its price is whatever they can take. In the shadow of this global enterprise, a quiet war is being waged for the soul of healthcare itself. On one side stands a for-profit model designed for extraction. On the other stands Australia’s Pharmaceutical Benefits Scheme (PBS), a bastion of public health now under sustained assault.

This is an investigation into the machinery of that assault.

The Bulwark: Australia’s PBS

Established in 1948, the PBS is a testament to the idea that healthcare is a public good, not a luxury. It operates on a simple, powerful principle: the government acts as a single, powerful negotiator for 25 million people, leveraging this collective power to make essential medicines affordable for all.

The scheme is available to every Australian with a Medicare card. As of 2025, the maximum co-payment is $31.60** for general patients and **$7.70 for concession card holders. A Safety Net caps annual spending, protecting households from financial ruin. The scheme’s integrity is guarded by the independent Pharmaceutical Benefits Advisory Committee (PBAC), which rigorously assesses whether a new drug is clinically effective and cost-effective enough to be listed. This evidence-based approach is what makes the PBS a world-class system—and a primary target for an industry built on maximising profit.

The Assault: American Pressure and the Profit Motive

The U.S. pharmaceutical industry, where prices are on average 370% higher than in Australia, views the PBS as an “egregious and discriminatory” barrier to profits. Their campaign is multi-pronged and relentless.

Their goal is to force a system where “the market” (i.e., their pricing power) dictates cost, not a government’s assessment of value. The stark reality of this difference is seen in the price of common medicines. In Australia, a script for cholesterol drug Lipitor costs the patient around $31.60**. In the U.S., the same drug can cost **around $2,000. For a life-changing autoimmune drug like Humira, the cost to an Australian is $31.60**, while an American faces a bill of approximately **$11,000. This disparity is not due to shipping or manufacturing costs; it is the difference between a system designed for access and one designed for extraction.

A major victory for this campaign was the 2005 Australia-U.S. Free Trade Agreement. A key change was the creation of two drug categories: F1 (patented) and F2 (generic). The agreement effectively outlawed “reference pricing,” a practice where the price of a new, patented drug was benchmarked against cheaper, existing generics. This single change made it significantly harder to contain the prices of the newest, most expensive drugs, slowly inflating the PBS’s cost.

The Illusion: Research & Development vs. Marketing & Profit

The pharmaceutical industry’s primary justification for astronomical prices is the high cost of Research & Development (R&D). The data reveals a different story.

A global analysis of the 20 largest pharmaceutical companies during the peak pandemic years (2020-2022) found they spent a combined $377.6 billion on dividends, share buybacks, and executive compensation. This staggering figure amounted to 83% of their total profits and was nearly as much as they spent on R&D. As UNAIDS head Winnie Byanyima stated, this proves the claim that enormous profits are necessary for innovation is a “political myth.”

The financial priorities of the industry are clear. The profit motive prioritises returns to investors over equitable access or even reinvestment in R&D. Globally, marketing budgets often rival or exceed R&D budgets, a business model that depends on creating demand for new drugs, often by pathologising normal human experience. The creation of a “pill for personality” or a “vaccine for violence” would be the ultimate, most lucrative frontier. The slope is not just greased; it is a downhill racetrack.

The Defences: Regulatory Capture and Legal Labyrinths

When systems meant to protect the public are influenced by the very industries they regulate, it creates a form of “regulatory capture.”

Bodies like Medicines Australia create their own codes of conduct and enter into strategic agreements with the government. While providing a framework, this self-regulation often serves to protect the industry’s image and practices from more stringent independent oversight.

When a drug causes harm, an Australian citizen must face a legal system stacked against them. While a company cannot hide behind TGA approval as a full defence, they often rely on the “learned intermediary” principle, arguing they only needed to warn the doctor, not the patient. Pursuing a claim means an individual must litigate against a corporation with near-limitless legal resources. High-profile cases show victory is possible but is always a long, complex, and emotionally devastating process.

The Silent Crisis: The Unreported Harm

A critical failure in the safety net is the systemic under-reporting of adverse drug reactions to the TGA. Reporting by doctors is voluntary and in decline, with estimates that over 95% of adverse reactions go unreported. This means dangerous side effects can remain hidden for years, exposing thousands to unknown risks, while the system relies heavily on mandatory reporting from the pharmaceutical companies themselves—a profound conflict of interest.

Conclusion: A Choice of Futures

The battle for the PBS is a proxy for a larger conflict. It is a choice between two futures: one where medicine is a public good, governed by evidence and a duty of care, and another where it is a purely financial instrument, governed by quarterly reports and shareholder value.

The pressure to abandon our model for their profit will only intensify. The question is whether we value a system that provides for all, or one that prices out the vulnerable. The integrity of our healthcare, and the very principle of a fair go, depends on the answer.

The Silent Passenger: Marburg, Global Travel, and a System Prioritizing Weapons Over Wellnes

Posted on by
Reply

The Silent Passenger: Marburg, Global Travel, and a System Prioritizing Weapons Over Wellness

By Andrew Klein 

A new outbreak of the deadly Marburg virus has been confirmed in Ethiopia, a stark reminder of an ever-present threat. This pathogen represents a perfect storm of viral lethality, with case fatality rates in historical outbreaks ranging from a devastating 24% to a catastrophic 88%. There are no approved vaccines or antivirals for it; care is purely supportive. Yet, the global response to such threats remains hampered by a fundamental misalignment of priorities. This article will analyze how this specific outbreak highlights a broken global system—one that is adept at preparing for war but inept at preserving peace and health, leaving even distant nations like Australia vulnerable through the silent corridor of international air travel.

The Nature of the Threat: A Persistent and Deadly Foe

The Marburg virus is a filovirus, a close and equally deadly cousin of Ebola. Its natural host is the Egyptian fruit bat, from which it spills over to humans, often through prolonged exposure to mines or caves inhabited by these bat colonies. Once in the human population, it spreads relentlessly through direct contact with the bodily fluids of infected individuals.

The history of this pathogen is a ledger of tragedy. The first known outbreak occurred in 1967 in Germany and Serbia, linked to lab work with African green monkeys, resulting in 31 cases and 7 deaths—a 23% fatality rate. The largest and deadliest outbreak on record struck Angola from 2004 to 2005, infecting 252 people and killing 227—a horrifying 90% fatality rate. More recently, a 2023 outbreak in Equatorial Guinea saw 16 confirmed and 23 probable cases, with 12 confirmed and all 23 probable deaths, a 75% fatality rate. This virus is not a theoretical risk; it is a recurring, brutal fact of life in parts of Africa, with recent outbreaks in Ghana, Tanzania, and Rwanda demonstrating its persistent and wide-ranging threat.

The Australian Gateway: A Calculated Risk via Modern Travel

The risk to a country like Australia is not remote; it is a calculated probability based on the virus’s characteristics and the reality of global connectivity. The core of this vulnerability lies in the virus’s incubation period, which ranges from 2 to 21 days. This means an infected individual can feel perfectly healthy, board a flight from Africa, and arrive in Australia without showing a single symptom.

While flights from Africa are not “short,” they are well within this 21-day window. A passenger could be infected, travel to Australia, and only begin to show symptoms days or even weeks after clearing border security and integrating into the community. Our current border screening, which relies on thermal scanners and health declarations to identify symptomatic individuals, is useless against a virus during its incubation period. This creates a silent corridor for the virus to enter the country. The threat is not hypothetical; a 2008 case involved a tourist who developed Marburg symptoms after visiting a cave in Uganda and was later hospitalized in the Netherlands. The pathway to Australia is just as feasible.

The Systemic Failure: A World Armed for War, Unprepared for Care

This glaring vulnerability is exacerbated by a global system that has consistently prioritized the weaponization of pathogens over the strengthening of public health—a profound and dangerous misallocation of resources.

Following the 2001 anthrax attacks in the United States, funding for biodefense surged dramatically. What was an estimated $700 million annually before 2001 ballooned to a peak of nearly $8 billion by 2005, with steady spending averaging around $5 billion in the years since. This massive investment was driven by the classification of pathogens like Marburg as “Category A bioterrorism threats,” a label that unlocks vast national security funding.

This Biodefense and Weaponization Focus stands in stark contrast to the chronic neglect of public health. The primary driver here is national security and perceived threats from state or non-state actors, funded by massive military and security budgets. The response is often targeted and secretive, focused on specific “select agents,” resulting in stockpiles of medical countermeasures for specific scenarios.

Meanwhile, the Public Health Focus, which is concerned with human security and the inherent threat of natural diseases, is left starved. Organizations like the World Health Organization (WHO) are crippled by a financial structure where over 80% of their budget comes from voluntary contributions that donors control. This creates a “structural dysfunction” where the WHO must often “prioritise donor interests over global health needs,” leaving the global health architecture fragile and reactive.

The disparity is starkly visible in vaccine development. In 2019, the U.S. Department of Defence awarded $35.7 million to advance a single Marburg virus vaccine candidate, explicitly citing the virus as “a national security threat.” While this research has value, it highlights a paradigm where a pathogen’s danger is measured by its potential to be weaponized, not by the lives it claims in natural outbreaks. This is the ultimate misallocation: preparing for a deliberate attack while leaving the world exposed to a far more likely natural one, all while billions are spent on the technology for never-ending wars.

The Path Forward: From Reactive Panic to Proactive Resilience

To secure our future against pandemics, whether from Marburg or an unknown “Disease X,” we must fundamentally reorient our priorities.

1. Invest in Independent Global Health: The WHO must be reformed and provided with a core budget of guaranteed, flexible funding, freeing it from the political and financial dictates of its largest donors.

2. Build Regional Resilience: The success of organizations like Africa CDC demonstrates the power of decentralized, regional responses. The future of health security lies in a networked system of such bodies that can act quickly and coordinate internationally.

3. Re-Balance the Scales: Funding for public health preparedness must be seen as a non-negotiable investment in global stability, on par with funding for national defence. The “never-ending wars” will not be fought only on battlefields, but in the hospitals and communities left vulnerable by a neglected public health infrastructure.

The Marburg outbreak in Ethiopia is a warning. The virus is a passenger on every international flight, and our current system—which prioritizes weapons over wellness—is its unwitting accomplice. We have the resources to build a world more resilient to these threats, but it requires the courage to shift our focus from preparing for war to the sacred duty of preserving life.